Promoting Adherence to Anti-HIV Drug Regimens - Full Text View

Purpose

One of the main causes of treatment failure in HIV infected individuals is lack of adherence to complicated drug regimens. The purpose of this study is to evaluate the effectiveness of a behavioral intervention program designed to improve adherence to anti-HIV drug regimens. Participants in this study will be recruited from the University of Alabama at Birmingham (UAB) Outpatient HIV Clinic.

Condition	Intervention
HIV Infections	Behavioral: Promotion of adherence to ARV medications


Study Type:	Interventional
Study Design:	Allocation: Randomized Intervention Model: Parallel Assignment
Official Title:	Promoting Adherence to Antiretroviral Regimens

Resource links provided by NLM:

MedlinePlus related topics: HIV/AIDS

U.S. FDA Resources

Further study details as provided by National Institute of Allergy and Infectious Diseases (NIAID):

Primary Outcome Measures:

Pill counts for ARV medications

Secondary Outcome Measures:

Viral load
disease progression measures (CD4 count, viral resistance)
self-reported adherence
self-reported psychosocial measures


Estimated Enrollment:	119
Study Start Date:	August 2002
Study Completion Date:	July 2006

Detailed Description:

Poor adherence to complicated antiretroviral (ARV) drug regimens is one of the most pressing behavioral problems in the clinical management of HIV infected persons. Recent medical advances have made it possible to maintain tighter control of viral replication, allowing people with HIV to live longer, healthier lives. However, the complexity of ARV drug regimens and drug side effects make medication adherence problematic. Deviations from the prescribed regimen may allow the virus to resume rapid replication and develop drug resistant mutations that could render the prescribed drugs useless. This study will evaluate the efficacy of a 6-month, theory-based behavioral intervention to enhance adherence to antiretroviral treatment regimens. HIV-related attitudes, depressive symptoms, coping strategies, and social support will also be assessed to examine theoretical assumptions regarding the causal relationship between psychosocial constructs and medication adherence.

Participants in this study will be recruited from UAB Outpatient HIV Clinic patients who are taking ARV medication. Participants will be randomized to a Standard Adherence Promotion Group or an Enhanced Adherence Promotion Group. The Enhanced Adherence Promotion will systematically address specific psychosocial issues associated with medication adherence. Participants will be followed for 6 months, and adherence will be evaluated at monthly study visits. Pill counts, viral loads, self-reported adherence to ARV medication, CD4 count, and genotypic viral resistance will be assessed.

Eligibility


Ages Eligible for Study:	19 Years and older (Adult, Senior)
Sexes Eligible for Study:	All
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria

HIV infected
Receiving services at UAB Outpatient HIV Clinic
Taking antiretroviral medication
Able to attend monthly assessment meetings at clinic for 6 months
Passing score on Mini Mental State Examination

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00051805

Locations


United States, Alabama
University of Alabama at Birmingham Outpatient HIV Clinic
Birmingham, Alabama, United States, 35294

Sponsors and Collaborators

National Institute of Allergy and Infectious Diseases (NIAID)

Investigators


Principal Investigator:	Polly Kratt, PhD, MSPH	University of Alabama at Birmingham Outpatient HIV Clinic

More Information

Additional Information:

Click here for more information on adherence This link exits the ClinicalTrials.gov site

Click here for more information on adhering to a regimen This link exits the ClinicalTrials.gov site

Publications:

Stewart KE,Greene PG,Ross D,Kratt P, Balentine C, Lee P, Wang Y. Sex, drugs, and viral load: Associations in an HIV+ cohort. In: Society of Behavioral Medicine, 27th Annual Meeting & Scientific Sessions; 2006 Mar 23; San Francisco [CA]: Behavioral Medicine Across the Lifespan. Session Abstracts & Program Information Vol. 31, No. suppl. 1, Pages i-I.


ClinicalTrials.gov Identifier:	NCT00051805 History of Changes
Obsolete Identifiers:	NCT00078780
Other Study ID Numbers:	1R01AI045403-01A2 ( U.S. NIH Grant/Contract ) 3R01AI045403-02S1 ( U.S. NIH Grant/Contract ) 5R01AI045403-03 ( U.S. NIH Grant/Contract )
Study First Received:	January 16, 2003
Last Updated:	September 17, 2007

Keywords provided by National Institute of Allergy and Infectious Diseases (NIAID):


Patient Compliance Adherence Treatment Experienced

Additional relevant MeSH terms:


HIV Infections Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases	Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases

ClinicalTrials.gov processed this record on August 16, 2017